160 related articles for article (PubMed ID: 26169313)
1. Metabolic alterations in renal cell carcinoma.
Massari F; Ciccarese C; Santoni M; Brunelli M; Piva F; Modena A; Bimbatti D; Fantinel E; Santini D; Cheng L; Cascinu S; Montironi R; Tortora G
Cancer Treat Rev; 2015 Nov; 41(9):767-76. PubMed ID: 26169313
[TBL] [Abstract][Full Text] [Related]
2. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.
Badoiu SC; Greabu M; Miricescu D; Stanescu-Spinu II; Ilinca R; Balan DG; Balcangiu-Stroescu AE; Mihai DA; Vacaroiu IA; Stefani C; Jinga V
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176098
[TBL] [Abstract][Full Text] [Related]
4. Aerobic glycolysis: a novel target in kidney cancer.
Shuch B; Linehan WM; Srinivasan R
Expert Rev Anticancer Ther; 2013 Jun; 13(6):711-9. PubMed ID: 23773105
[TBL] [Abstract][Full Text] [Related]
5. The genetic basis of kidney cancer: a metabolic disease.
Linehan WM; Srinivasan R; Schmidt LS
Nat Rev Urol; 2010 May; 7(5):277-85. PubMed ID: 20448661
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs and altered metabolism of clear cell renal cell carcinoma: Potential role as aerobic glycolysis biomarkers.
Morais M; Dias F; Teixeira AL; Medeiros R
Biochim Biophys Acta Gen Subj; 2017 Sep; 1861(9):2175-2185. PubMed ID: 28579513
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming in renal cancer: Events of a metabolic disease.
Chakraborty S; Balan M; Sabarwal A; Choueiri TK; Pal S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188559. PubMed ID: 33965513
[TBL] [Abstract][Full Text] [Related]
9. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
10. Metabolic alterations in hereditary and sporadic renal cell carcinoma.
Coffey NJ; Simon MC
Nat Rev Nephrol; 2024 Apr; 20(4):233-250. PubMed ID: 38253811
[TBL] [Abstract][Full Text] [Related]
11. Reprogramming of Metabolism in Kidney Cancer.
Wettersten HI
Semin Nephrol; 2020 Jan; 40(1):2-13. PubMed ID: 32130963
[TBL] [Abstract][Full Text] [Related]
12. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer.
Langbein S; Frederiks WM; zur Hausen A; Popa J; Lehmann J; Weiss C; Alken P; Coy JF
Int J Cancer; 2008 Jun; 122(11):2422-8. PubMed ID: 18302154
[TBL] [Abstract][Full Text] [Related]
13. SnapShot: Renal Cell Carcinoma.
Ricketts CJ; Crooks DR; Sourbier C; Schmidt LS; Srinivasan R; Linehan WM
Cancer Cell; 2016 Apr; 29(4):610-610.e1. PubMed ID: 27070709
[TBL] [Abstract][Full Text] [Related]
14. New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.
Srinivasan R; Ricketts CJ; Sourbier C; Linehan WM
Clin Cancer Res; 2015 Jan; 21(1):10-7. PubMed ID: 25564569
[TBL] [Abstract][Full Text] [Related]
15. Renal carcinogenesis--insights into signaling pathways.
Cojocaru E; Lozneanu L; Giuşcă SE; Căruntu ID; Danciu M
Rom J Morphol Embryol; 2015; 56(1):15-9. PubMed ID: 25826482
[TBL] [Abstract][Full Text] [Related]
16. The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.
Lameirinhas A; Miranda-Gonçalves V; Henrique R; Jerónimo C
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30986931
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
Sudarshan S; Pinto PA; Neckers L; Linehan WM
Nat Clin Pract Urol; 2007 Feb; 4(2):104-10. PubMed ID: 17287871
[TBL] [Abstract][Full Text] [Related]
19. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
20. The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy.
Kaminska K; Szczylik C; Lian F; Czarnecka AM
Future Oncol; 2014 Nov; 10(14):2177-87. PubMed ID: 25471032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
